Santhera Pharmaceuticals Holding AG/€SANN
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG is a Swiss pharmaceutical company focused on the development and commercialization of innovative treatments for rare and debilitating diseases. The company's key areas of expertise include neuromuscular and pulmonary disorders. Santhera's product pipeline features several investigational drugs targeting conditions such as Duchenne muscular dystrophy and cystic fibrosis. Headquartered in Pratteln, Switzerland, the company leverages its scientific expertise and industry partnerships to advance its therapeutic offerings. Santhera's strategic focus on niche markets allows it to address unmet medical needs, providing potential opportunities for growth within specialized segments of the healthcare industry.
Ticker
€SANN
Sector
Primary listing
XGAT
Employees
79
Headquarters
Pratteln, Switzerland
Website
SANN Metrics
BasicAdvanced
€174M
-
-€5.77
-0.74
-
Price and volume
Market cap
€174M
Beta
-0.74
52-week high
€18.80
52-week low
€8.51
Average daily volume
10K
Financial strength
Current ratio
1.018
Quick ratio
0.512
Long term debt to equity
-1,318.182
Total debt to equity
-1,608.35
Interest coverage (TTM)
-5.95%
Profitability
EBITDA (TTM)
-48.702
Gross margin (TTM)
13.41%
Net profit margin (TTM)
-133.72%
Operating margin (TTM)
-103.75%
Effective tax rate (TTM)
-0.33%
Revenue per employee (TTM)
€661,710
Management effectiveness
Return on assets (TTM)
-26.60%
Return on equity (TTM)
-288.14%
Valuation
Price to revenue (TTM)
3.018
Price to book
-61.57
Price to tangible book (TTM)
-2.29
Price to free cash flow (TTM)
-3.608
Free cash flow yield (TTM)
-27.71%
Free cash flow per share (TTM)
-3.608
Growth
Revenue change (TTM)
-56.85%
Earnings per share change (TTM)
-194.97%
3-year revenue growth (CAGR)
569.96%
10-year revenue growth (CAGR)
31.31%
3-year earnings per share growth (CAGR)
-24.51%
10-year earnings per share growth (CAGR)
-13.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Santhera Pharmaceuticals Holding AG stock?
Santhera Pharmaceuticals Holding AG (SANN) has a market cap of €174M as of December 07, 2025.
What is the P/E ratio for Santhera Pharmaceuticals Holding AG stock?
The price to earnings (P/E) ratio for Santhera Pharmaceuticals Holding AG (SANN) stock is 0 as of December 07, 2025.
Does Santhera Pharmaceuticals Holding AG stock pay dividends?
No, Santhera Pharmaceuticals Holding AG (SANN) stock does not pay dividends to its shareholders as of December 07, 2025.
When is the next Santhera Pharmaceuticals Holding AG dividend payment date?
Santhera Pharmaceuticals Holding AG (SANN) stock does not pay dividends to its shareholders.
What is the beta indicator for Santhera Pharmaceuticals Holding AG?
Santhera Pharmaceuticals Holding AG (SANN) has a beta rating of -0.74. This means that it has an inverse relation to market volatility.